-
The Experience
-
About Stanford GSB
About Our Degree Programs
-
-
The Programs
-
Full-Time Degree Programs
Non-Degree & Certificate Programs
-
-
Faculty & Research
-
Faculty
Faculty Research
Research Hub
Centers & Initiatives
-
-
Insights
-
Topics
-
-
Alumni
-
Welcome, Alumni
-
-
Events
-
Admission Events & Information Sessions
-
Insights by Stanford Business
Latest Stories
November 7, 2019
Exploring the Human Side of Artificial Intelligence
At an AI forum, experts say the arrival of superhuman machine intelligence will be one of the biggest events in human history.
November 4, 2019
Narcissistic CEOs Weaken Collaboration and Integrity
Some may be bold leaders, but they create a dangerous corporate culture.
November 4, 2019
Why Great Businesses Fail
Strong leadership makes a difference when a big company faces disruption.
October 31, 2019
Has California Hit the Limit on Tax Rates?
A study finds that almost half of the state’s 2012 income tax increase was eroded by people who moved away or lowered their taxable income.
October 28, 2019
Big Data and Racial Bias: Can That Ghost Be Removed from the Machine?
Credit-market algorithms may violate anti-discrimination laws even when they’re designed not to. A Stanford researcher looks for a fix.
October 28, 2019
The Mixed Impact of U.S. Corporate Tax Cuts
Slashing business taxes brings some local investment but fewer overall U.S. jobs, new research finds.
October 24, 2019
Cryptocurrencies Could Eliminate Banking’s Easiest Moneymaker
Banks earn big profits by paying minuscule interest on deposits and charging large credit card fees. Digital currencies are about to disrupt that.
October 22, 2019
How Stanford GSB Alums Created One of the Most Valuable Startups in Latin America
São Paulo-based Nubank, valued at $10 billion, is disrupting the region’s banking sector.
October 18, 2019
How Corporations Use Tax Havens to Maximize Profits
What does it mean for a company to pay its fair share?
October 18, 2019
Turning the Pharmaceutical Model Upside-Down
How a nonprofit gave birth to a company that aims to disrupt Big Pharma.











